Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trialстатья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или Scopus
Авторы:
Gutzmer Ralf,
Stroyakovskiy Daniil,
Gogas Helen,
Robert Caroline,
Lewis Karl,
Protsenko Svetlana,
Pereira Rodrigo P.,
Eigentler Thomas,
Rutkowski Piotr,
Demidov Lev,
Manikhas Georgy Moiseevich,
Yan Yibing,
Huang Kuan-Chieh,
Uyei Anne,
McNally Virginia,
McArthur Grant A.,
Ascierto Paolo A.
Аннотация:IMspire150 aimed to evaluate first-line combination treatment with BRAF plus MEK inhibitors and immune checkpoint therapy in BRAFV600 mutation-positive advanced or metastatic melanoma.